This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Jul;188(1):108-9.

doi: 10.1016/j.juro.2012.03.135. Epub 2012 May 12.

Editorial comment

Himisha Beltran, Scott Tagawa

PMID: 22583643
DOI: 10.1016/j.juro.2012.03.135

Editorial

Editorial comment

Himisha Beltran et al. J Urol. 2012 Jul.

. 2012 Jul;188(1):108-9.

doi: 10.1016/j.juro.2012.03.135. Epub 2012 May 12.

Authors

Himisha Beltran, Scott Tagawa

PMID: 22583643
DOI: 10.1016/j.juro.2012.03.135

No abstract available

PubMed Disclaimer

Comment on

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS. Yu EY, et al. J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12. J Urol. 2012. PMID: 22583636 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information